Table 2.

Masked drug profiles used in explicit choice analyses

	Medication X (comparable to empagliflozin 2.5 mg q.d.)	Medication Y (comparable to sotagliflozin 400 mg q.d.)	Medication Z (comparable to pramlintide 60 μg t.i.d.)
Treatment form	A pill once a day	A pill once a day	Injections three times a day
HbA1c reduction	0.28% (3.1 mmol/mol)	0.46% (5.0 mmol/mol)	0.23% (2.5 mmol/mol)
Weight reduction	4 lbs (1.8 kg)	6.5 lbs (3 kg)	4.4 lbs (2 kg)
Risk of DKA	No change	5 times increase	No change
Risk of severe hypoglycemia	No change	No change	2 times increase
Risk of diarrhea	No change	2 times increase	No change
Risk of nausea	No change	No change	4 times increase
Risk of genital infection	2 times increase	3 times increase	No change